Pangaea Oncology, S.A.
PANG
Rank in Stocks
#22031
Pangaea Oncology, S.A. delivers essential medical services to cancer patients... Pangaea Oncology, S.A. delivers essential medical services to cancer patients across Spain and other European Union countries. Its extensive offerings encompass advanced molecular diagnostics, which include mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression profiling. The company is also active in clinical trials and provides in vitro drug profiling, employing techniques like MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing. Furthermore, Pangaea operates a specialized Dx platform for validating companion diagnostic platforms, benchmarking them against commercial alternatives, and offering bespoke research and development services to other diagnostic firms. A key focus also involves biomarker discovery, aiming to pinpoint novel targets for targeted therapies in their pre-clinical stages. Established in 2006, Pangaea Oncology, S.A. is headquartered in Barcelona, Spain.
Share Price
$1.64
Last synced: 2026-11-09
Market Cap
$58.90M
Change (1 day)
-0.67%
Change (1 year)
-19.53%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Pangaea Oncology, S.A. (PANG)
Category
Healthcare
EPS for Pangaea Oncology, S.A. (PANG)
EPS as of December 2025 TTM: $-0.12
According to Pangaea Oncology, S.A.'s latest financial reports, its current EPS (TTM) is $-0.12. At the end of 2025 the company had an EPS of $-0.13, a decrease compared to its 2024 EPS of $-0.04.
EPS history for Pangaea Oncology, S.A. from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.12 | -9.77% |
| 2025 | $-0.13 | 223.56% |
| 2024 | $-0.04 | -75.93% |
| 2023 | $-0.17 | 73.43% |
| 2022 | $-0.10 | 198.75% |
| 2021 | $-0.03 | -72.17% |
| 2020 | $-0.12 | -63.40% |
| 2019 | $-0.31 | 190.12% |
| 2018 | $-0.11 | -39.83% |
| 2017 | $-0.18 | 209.81% |
| 2016 | $-0.06 | 18.33% |
| 2015 | $-0.05 | 123.18% |
| 2014 | $-0.02 | -322.22% |
| 2013 | $0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $18.99 | -16,289.26% |
US
|
|
| $6.12 | -5,317.39% |
US
|
|
| $1.38 | -1,274.00% |
CN
|
|
| $14.83 | -12,742.80% |
US
|
|
| $5.09 | -4,439.30% |
US
|
Questions about Pangaea Oncology, S.A.'s earnings per share (EPS)
What is Pangaea Oncology, S.A.'s earnings per share (EPS)?
Pangaea Oncology, S.A.'s earnings per share (EPS) over the last twelve months is $-0.12, as of Dec 2025.
What was Pangaea Oncology, S.A.'s earnings per share (EPS) in 2025?
In 2025, Pangaea Oncology, S.A.'s earnings per share (EPS) was $-0.13, compared with $-0.04 in 2024.
How has Pangaea Oncology, S.A.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Pangaea Oncology, S.A.'s earnings per share (EPS) was highest in 2021 ($-0.03) and lowest in 2023 ($-0.17).
How does Pangaea Oncology, S.A.'s earnings per share (EPS) compare with similar companies?
Pangaea Oncology, S.A.'s earnings per share (EPS) ($-0.12) is lower than that of all 5 similar companies listed above. The highest among them is Thermo Fisher Scientific Inc., with $18.99.